SCHEMBL12499481

SCHEMBL12499481

COC(=O)c1c(OS(=O)(=O)C(F)(F)F)c2ccccc2c(=O)n1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.43
KDM4E B2RXH2 2/20 0.43
HPGD P15428 2/20 0.43
HSD17B10 Q99714 1/20 0.43
LMNA P02545 1/20 0.42
BRD4 O60885 2/20 0.42
PABPC1 P11940 1/20 0.41
EIF4H Q15056 1/20 0.41
MAPK8 P45983 2/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
TACR1 P25103 4/20 0.38
PDE3B Q13370 1/20 0.38
PDE3A Q14432 1/20 0.38
PGR P06401 2/20 0.38
NR1H3 Q13133 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
GAA P10253 1/20 0.37
GABRA1 P14867 1/20 0.36
GABRG2 P18507 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14809387 0.80 MAPK8 (0.40) KDM4EBRD4MAPK8
SCHEMBL12687183 0.80 EGFR (0.41) ALDH1A1KDM4EHPGDHSD17B10LMNA
SCHEMBL7003543 0.74 SMN1; SMN2 (0.49) ALDH1A1KDM4EHPGDHSD17B10LMNA
SCHEMBL4713112 0.74 MAPK8 (0.59) MAPK8
SCHEMBL5240374 0.74 ALDH1A1 (0.43) ALDH1A1KDM4EHPGDHSD17B10LMNA
SCHEMBL5235211 0.74 ALDH1A1 (0.43) ALDH1A1KDM4EHPGDHSD17B10LMNA
SCHEMBL8785395 0.72 MAPK8 (0.66) ALDH1A1KDM4ELMNABRD4MAPK8
SCHEMBL10518838 0.72 BRD4 (0.51) ALDH1A1KDM4EHPGDHSD17B10LMNA
SCHEMBL2012992 0.72 MEN1 (0.41) ALDH1A1KDM4EHPGDHSD17B10LMNA
SCHEMBL18566637 0.72 KDM4E (0.42) ALDH1A1KDM4EHPGDLMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9029391-B2 Isoquinoline compounds and methods for treating HIV VIIV HEALTHCARE UK LIMITED (GB) 2015-05-12 US disclosed
US-9029391-B2 Isoquinoline compounds and methods for treating HIV VIIV HEALTHCARE UK LIMITED (GB) 2015-05-12 US disclosed
US-9029391-B2 Isoquinoline compounds and methods for treating HIV VIIV HEALTHCARE UK LIMITED (GB) 2015-05-12 US disclosed
US-20130289027-A1 Isoquinoline Compounds And Methods For Treating HIV VIIV HEALTHCARE UK LIMITED (GB) 2013-10-31 US disclosed
US-20130289027-A1 Isoquinoline Compounds And Methods For Treating HIV VIIV HEALTHCARE UK LIMITED (GB) 2013-10-31 US disclosed
US-20130289027-A1 Isoquinoline Compounds And Methods For Treating HIV VIIV HEALTHCARE UK LIMITED (GB) 2013-10-31 US disclosed
WO-2012102985-A1 ISOQUINOLINE COMPOUNDS AND METHODS FOR TREATING HIV GLAXOSMITHKLINE LLC (US) 2012-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130289027-A1 Isoquinoline Compounds And Methods For Treating HIV MAVS, CCR5, NFATC1 ALDH1A1 3054/4885KDM4E 1767/4885HPGD 1692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.